The long half-life of semaglutide means it remains active in your body for weeks after your last injection
Those enrolled in government-sponsored insurance, such as Medicare or Medicai,d are not eligible
doi: 10.47102/annals-acadmedsg.2022358
Clinical implication: clinicians should treat vaginal symptoms in patients taking semaglutide as real and addressable , but approach causality cautiously: prioritise common diagnoses (genitourinary syndrome of menopause, infections, dermatologic vulvar disease, STIs, irritant/contact dermatitis, pelvic floor disorders), identify important confounders (notably SGLT2 inhibitors, antibiotics, hormonal therapies), manage symptoms and underlying conditions, and report suspected adverse reactions when there is a reasonable temporal relationship and alternative causes are less likely